Labcorp has expanded its molecular residual disease (MRD) testing portfolio to include monitoring for breast cancer recurrence. The company’s Plasma Detect ID test is now available for patients with stage I–III breast cancer, alongside expanded offerings for non-small cell lung cancer and colon cancer.
MRD testing detects small traces of circulating tumor DNA in a patient’s blood following treatment, potentially signaling recurrence months before it would appear on traditional imaging. Breast cancer recurrence rates range from 10% to 40% for patients with stage I–III disease.
“For patients who have completed cancer treatment with curative intent, ongoing monitoring is essential to understand their risk of recurrence,” said Shakti Ramkissoon, Vice President and Medical Lead for Oncology at Labcorp. “By expanding the Labcorp Plasma Detect portfolio, we’re giving clinicians advanced tools to track molecular residual disease and detect recurrence risk earlier, supporting more personalized and proactive care.”
The test can detect circulating tumor DNA down to a limit of detection of 0.005%. According to the American Cancer Society’s Cancer Statistics 2026 report, the five-year relative survival rate across all cancers has reached 70% for the first time, meaning more patients are entering long-term surveillance where MRD testing may play an increasing role.
